Proteros Biostructures GmbH. (3/16/11). "Press Release: Proteros and CHDI Foundation, Inc. Establish Discovery Services Collaboration to Address Huntington’s Disease". Martinsried.

	Organisation	Proteros Biostructures GmbH
	Group	Proteros (Group)
	Product	structure-based drug design
	Product 2	drug discovery services
	Person	D’Cruz, Cony (Proteros 201008– CBO + President Proteros US Inc before Evotec SVP North America)
	Person 2	Herrenknecht, Kurt (SciArcum 201110– before Proteros + Zukunftsfonds Heilbronn + PerkinElmer + Evotec + Eisai)

Proteros Biostructures GmbH (Proteros) announced today that it has entered into a service agreement with CHDI Foundation, Inc. (CHDI), under which Proteros will provide structure-based drug discovery services to CHDI. Proteros will apply its integrated discovery platform including proprietary X-ray crystallography tools to help CHDI in its mission to develop therapeutics that slow the progression of Huntington.s disease (HD).

Cony D.Cruz Chief Business Officer and President Proteros US, Inc. stated, “CHDI has been at the forefront of using a best-in-class network to assist in developing therapies for HD. We welcome the opportunity for Proteros to contribute to this effort.”

About Proteros:

Proteros is a privately held company that provides services and proprietary technologies to support integrated drug discovery. Proteros uses its technical expertise, industrial processes and unique technologies for crystallography, kinetic and thermodynamic profiling and fragment-based lead generation incorporating protein structure inspired compound and fragment libraries. The platform enables .knowledge driven lead engineering. to accelerate and improve protein structure analysis and structure-based drug discovery. Proteros complements its clients. internal capabilities with external expertise and access to flexible resources. Proteros currently provides services to more than 80 pharmaceutical and biotechnology clients in North America, Europe and Japan. Proteros US, Inc. is a wholly owned subsidiary of Proteros established to serve the growing customer base in North America.

About CHDI Foundation:

CHDI Foundation, Inc. is a privately-funded, not-for-profit, scientific organization exclusively dedicated to rapidly discovering and developing therapies that slow the progression of Huntington.s disease. As a collaborative enabler, CHDI seeks to bring the right partners together to identify and address critical scientific issues and move drug candidates to clinical evaluation as quickly as possible. CHDI scientists work closely with a network of more than 600 researchers in academic and industrial laboratories around the world in the pursuit of these novel therapies, providing project management to ensure that our common goals remain in focus. More information about CHDI can be found at www.chdifoundation.org.

Contact:

Proteros biostructures GmbH
Kurt Herrenknecht, Ph.D.
Am Klopferspitz 19
82152 Martinsried
Germany
Phone: +49 (0) 89 7007 61 0
E-Mail: herrenknecht@proteros.com
Internet: www.proteros.com

CHDI Foundation, Inc.
Simon Noble, Ph.D.
Director, Scientific Communications
CHDI Management/CHDI Foundation
Phone: +1 212 660 8112
E-Mail: Simon.noble@chdifoundation.org
Internet: www.chdifoundation.org

Record changed: 2011-11-25

Top News

Upcoming Events

Bio Regions & Life Sciences Clusters

Business Parks & Science Centres

Associations

Partners

Proteros Biostructures GmbH. (3/16/11). "Press Release: Proteros and CHDI Foundation, Inc. Establish Discovery Services Collaboration to Address Huntington’s Disease". Martinsried.

More documents for Proteros (Group)